CoChat

A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients

Open access
Giraudet, Anne-Laure, Cassier, Philippe Alexandre, Iwao-Fukukawa, Chicaco, Garin, Gwenaelle, Badel, Jean-Noël, Kryza, David, Chabaud, Sylvie, Gilles-Afchain, Laurence, Clapisson, Gilles, Desuzinges, Claude, Sarrut, David, Halty, Adrien, Italiano, Antoine, Mori, Masaharu, Tsunoda, Takuya, Katagiri, Toyomasa, Nakamura, Yusuke, Alberti, Laurent, Cropet, Claire, Baconnier, Simon, Berge-Montamat, Sandrine, Pérol, David, Blay, Jean-Yves · 2018 · BMC Cancer
Cited by 63

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Synovial Sarcomas (SS) are rare tumors occurring predominantly in adolescent and young adults with a dismal prognosis in advanced phases. We report a first-in-human phase I of monoclonal antibody (OTSA-101) targeting FZD10, overexpressed in most SS but not present in normal tissues, labelled with radioisotopes and used as a molecular vehicle to specifically deliver radiation to FZD10 expressing SS lesions. Patients with progressive advanced SS were included. In the first step of this trial, OTSA-101 in vivo bio-distribution and lesions uptake were evaluated by repeated whole body planar and SPECT-CT scintigraphies from H1 till H144 after IV injection of 187 MBq of 111In-OTSA-101. A 2D dosimetry study also evaluated the liver absorbed dose when using 90Y-OTSA-101. In the second step, those patients with significant tumor uptake were randomized between 370 MBq (Arm A) and 1110 MBq (Arm B) of 90Y-OTSA-101 for radionuclide therapy. From January 2012 to June 2015, 20 pts. (median age 43 years [21–67]) with advanced SS were enrolled. Even though 111In-OTSA-101 liver uptake appeared to be intense, estimated absorbed liver dose was less than 20 Gy for each patient. Tracer intensity was greater than mediastinum in 10 patients consistent with sufficient tumor uptake to proceed to treatment with 90Y-OTSA-101: 8 were randomized (Arm A: 3 patients and Arm B: 5 patients) and 2 were not randomized due to worsening PS. The most common Grade ≥ 3 AEs were reversible hematological disorders, which were more frequent in Arm B. No objective response was observed. Best response was stable disease in 3/8 patients lasting up to 21 weeks for 1 patient. Radioimmunotherapy targeting FZD10 is feasible in SS patients as all patients presented at least one lesion with 111In-OTSA-101 uptake. Tumor uptake was heterogeneous but sufficient to select 50% of pts. for 90Y-OTSA-101 treatment. The recommended activity for further clinical investigations is 1110 MBq of 90Y-OTSA-101. However, because of hematological toxicity, less energetic particle emitter radioisopotes such as Lutetium 177 may be a better option to wider the therapeutic index. The study was registered on the NCT01469975 website with a registration code NCT01469975 on November the third, 2011.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-018-4544-x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 63

Metadata

Authors
Giraudet, A.-L., Cassier, P. A., Iwao-Fukukawa, C., Garin, G., Badel, J.-N., Kryza, D., Chabaud, S., Gilles-Afchain, L., Clapisson, G., Desuzinges, C., Sarrut, D., Halty, A., Italiano, A., Mori, M., Tsunoda, T., Katagiri, T., Nakamura, Y., Alberti, L., Cropet, C., Baconnier, S., Berge-Montamat, S., Pérol, D., & Blay, J.-Y.
Venue
BMC Cancer
Published
2018-06-08
Volume
18
Issue
1
Pages
646-646
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2805940486
Cited by
63
References
1
FWCI
4.25
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. https://app.cochat.ai/papers/10.1186/s12885-018-4544-x
The paper
Giraudet, A.-L., Cassier, P. A., Iwao-Fukukawa, C., Garin, G., Badel, J.-N., Kryza, D., Chabaud, S., Gilles-Afchain, L., Clapisson, G., Desuzinges, C., Sarrut, D., Halty, A., Italiano, A., Mori, M., Tsunoda, T., Katagiri, T., Nakamura, Y., Alberti, L., Cropet, C., . . . Blay, J.-Y. (2018). A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. https://doi.org/10.1186/s12885-018-4544-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.